Stock listing

Q32 Bio Inc.

Selected listing: 0T6G · LSE · USD · GB

Q32 Bio Inc. (LSE:0T6G), Health Technology. Latest release Sep 30, 2026: Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart…

0T6G:LSEUSDGBUpdated October 2, 2026

Ticker: LSE:0T6G
Asset type: Stock
Sector: Health Technology
Industry: Biotechnology
Exchange: LSE
Currency: USD

Latest news from Q32 Bio Inc.

Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026

September 30, 2026

Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026

September 29, 2026

Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Congress 2026

September 21, 2026

Q32 Bio Appoints José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer

September 14, 2026

Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 5, 2026

All Q32 Bio Inc. news →

Research Q32 Bio Inc.

Q32 Bio Inc. company profile

View the public company page for Q32 Bio Inc. on 6ix.

Q32 Bio Inc. news

Read company news and market updates connected to Q32 Bio Inc..

Q32 Bio Inc. investor events

Find investor webinars, events, and replay context for Q32 Bio Inc..